1.1Single-agent lurbinectedin treatment
Lurbinectedin is infused intravenously after progression of small-cell lung cancer following platinum-based chemotherapy. It binds to the DNA minor groove and disrupts transcription.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Lurbinectedin is infused intravenously after progression of small-cell lung cancer following platinum-based chemotherapy. It binds to the DNA minor groove and disrupts transcription.
Lurbinectedin and a PD-L1 antibody are administered by separate intravenous infusions during maintenance for extensive-stage small-cell lung cancer following platinum, etoposide, and PD-L1 antibody induction. Lurbinectedin disrupts transcription, and the antibody blocks PD-L1 signaling that suppresses T-cell activity.
Gemcitabine is infused on days 1 and 8, and docetaxel is infused after gemcitabine on day 8 of a 21-day cycle. Gemcitabine inhibits DNA synthesis, and docetaxel stabilizes microtubules and disrupts mitosis.
A single-agent soft-tissue sarcoma regimen delivers doxorubicin intravenously on day 1 of a 21-day cycle. Doxorubicin stabilizes topoisomerase II–DNA cleavage complexes and increases DNA strand breaks.
A breast cancer regimen administers 60 mg/m² of doxorubicin and 600 mg/m² of cyclophosphamide intravenously on day 1 of a 21-day cycle. Doxorubicin interferes with topoisomerase II, and activated cyclophosphamide metabolites cross-link DNA.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Patient-derived soft-tissue sarcoma organoids grow in a multiwell plate. Separate wells receive lurbinectedin, doxorubicin, both drugs, or vehicle alone, and the protocol records exposure as a concentration in the culture medium. Imaging measures organoid size and a viability assay measures the response after exposure.
A tumor spheroid assay pairs lurbinectedin with pegylated liposomal doxorubicin in place of free doxorubicin. Parallel wells contain lurbinectedin with free doxorubicin, each agent alone, or vehicle alone. The two combination groups receive the same nominal doxorubicin concentration based on total drug content, and imaging records the distribution of doxorubicin fluorescence across the spheroids.
A perfused tumor culture receives doxorubicin as two 60-minute pulses with 24 hours between pulse starts. Each pulse uses half the concentration of a single 60-minute reference pulse at the same flow rate, and drug-free medium flows between pulses. The lurbinectedin exposure schedule is identical in both groups, and imaging records cell death 48 hours after the first pulse starts.
An electronic medication administration record links lurbinectedin and doxorubicin entries to a common cycle identifier. Each doxorubicin entry stores the administered mass in milligrams, and the cycle record stores the verified body surface area in square meters. The record displays the total administered mass divided by that area alongside the configured per-cycle limit.
An echocardiography reporting system exports left ventricular ejection fraction and global longitudinal strain with the examination date. A clinical dashboard aligns those measurements with the dates of lurbinectedin and doxorubicin administration and displays the cumulative recorded doxorubicin dose at each examination. The dashboard flags missing baseline measurements and shows the change from baseline when a baseline result is available.
A liquid handler dispenses serial dilutions of lurbinectedin by row and doxorubicin by column in a cell culture plate. Control wells receive each drug alone or vehicle, with the final solvent concentration held constant across wells. A plate reader measures viability, and software maps the results to the paired concentrations using the dispensing record.
Doxorubicin and lurbinectedin are prepared in separate infusion containers and administered sequentially on the same treatment day. A compatible intravenous fluid flush clears residual solution from the shared tubing between infusions.
A noncoring needle accesses an implanted venous port for delivery of both drugs in the same cycle. Blood return is checked before doxorubicin administration to verify patency before delivery of the vesicant.
Each cycle contains one doxorubicin administration at 30 mg/m². The amount in milligrams is calculated by multiplying 30 by the patient's body surface area in square meters.
Each cycle contains one doxorubicin administration at 25 mg/m². A body surface area of 1.8 m² gives a total doxorubicin dose of 45 mg for that cycle.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The ET-743 is administered as part of a combination therapy with doxorubicin.A · US 2007/0082856 A1 · ¶ 28
In one embodiment, the method fur treating triple-negative metastatic breast cancer comprises administering to an individual in need thereof a dosing regimen which comprises at least one 3-week long treatment cycle, and wherein said individual is administered nonpegylated liposomal doxorubicin at a dose level of from 30 mg/m2 to 75 mg/m2 on day 1 of each treatment cycle, paclitaxel at a dose level of from 50 mg/m2 to 250 mg/m2 on day 1 of each treatment cycle, and at least onB · US 2015/0250723 A1 · ¶ 46
An empty cell means only that no passage was reproduced there.
The present invention is directed to the use of ecteinascidin 743 for cancer therapy, in particular to the use of ecteinascidin 743 in combination with another active drug, doxorubicin, for the treatment of cancer.A · US 2007/0082856 A1 · ¶ 2
However, the efficacy of available treatments on many cancer types is limited, and new, improved forms of treatment showing clinical benefit are needed.A · US 2007/0082856 A1 · ¶ 5
The trouble with this type of breast cancer is that it is better characterized by what it lacks rather than mutations that it has, making it difficult to identify treatments specific for this disease.B · US 2015/0250723 A1 · ¶ 5
In particular, doxorubicins use is limited by the potential for patients to suffer irreversible cardiotoxicity.B · US 2015/0250723 A1 · ¶ 6
patent.fyi, US 2026/0355187 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355187/, SHA-256 35e8237c2a4d0d4f7a19f76ac1357998a9bd3f7794d359db81e2862ab99cef6d